Eli Lilly Revises 2024 Adjusted EPS Guidance To $13.50-$14.00 Versus Prior Guidance Of $12.20-$12.70 And Consensus Of $12.46.
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has updated its 2024 adjusted EPS guidance to $13.50-$14.00, significantly higher than its previous forecast of $12.20-$12.70 and above the consensus estimate of $12.46.
April 30, 2024 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly has significantly raised its 2024 adjusted EPS guidance, indicating a stronger financial outlook than previously anticipated.
Raising the EPS guidance significantly above previous estimates and consensus indicates a strong confidence in future financial performance. This is likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100